ALK-Abelló

Foreign Filer Report • Sep 5, 2013

Copenhagen, 2013-09-05 14:59 CEST (GLOBE NEWSWIRE) --

ALK (OMX: ALK B) announces today that it has established a sponsored Level 1
American Depositary Receipt (ADR) programme in the United States.

An ADR is a US dollar denominated negotiable certificate that represents
ownership of shares in a non-US company. Each ADR is issued by a US depositary
bank and represents one or more shares of a foreign stock or a fraction of a
share. ADRs were specifically designed to facilitate the purchase, holding and
sale of non-US securities by US investors.

“The importance of North America to ALK continues to grow, with the expected
introductions of our new innovative allergy immunotherapy tablets via our
partnership with Merck," said Jens Bager, President & CEO of ALK. “US-based
investors are a significant part of our existing shareholder base. The
sponsored ADR programme provides a convenient alternative to meet their needs
as well as supporting ALK’s aim to expand the US shareholder base alongside our
growing business there.”

Deutsche Bank is acting as depositary bank for the ADR programme. ALK ADRs will
now be available for trading in the US over-the-counter (OTC) market, with five
ADRs representing one ALK share (5 ADR: 1 ordinary share). The ticker symbol is
AKABY.

                             ALK-Abelló A/S


                               Jens Bager
                          President & CEO

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is the world leader in allergy
immunotherapy – a unique treatment of the underlying cause of allergy. The
company has approximately 1,800 employees with subsidiaries, production
facilities and distributors worldwide. ALK has entered into partnership
agreements with Merck and Torii to commercialise allergy immunotherapy tablets
in North America and Japan, respectively. The company is headquartered in
Hørsholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information
at www.alk.net

About Sponsored Level 1 ADR programme
ADRs are US dollar-denominated negotiable instruments issued by a depositary
bank. The price of an ADR often tracks the price of the foreign stock in its
home market, adjusted for the ratio of ADRs to the company's shares, but may
vary according to other factors. Level 1 depositary receipts are the first
level of sponsored ADRs that can be issued and may only be traded on the OTC
market. When a company establishes a sponsored ADR programme, it appoints a
depositary bank which also acts as its US transfer agent.